▟ Vinebot intrinsic value, daily

← back

ABBV AbbVie

pharma · valued with opus medium conviction · deep-dived 2026-11-04

SELL
Intrinsic value$126.28
Price (at call)$286.00
Margin of safety -55.8%
vs market (rating basis) -25.1%

An immunology cash machine whose price already assumes Skyrizi and Rinvoq keep executing flawlessly for a decade.

The story

AbbVie got through the Humira biosimilar cliff faster than expected. Skyrizi and Rinvoq are now growing at double-digit rates and should together pass $31B by 2027, while neuroscience (Vraylar, migraine drugs, Parkinson's) adds a second growth leg. It is a mature, cash-rich pharma franchise. Reported margins look low because of Allergan intangible amortization and in-process R&D (IPR&D) charges from frequent business-development deals. The moat lasts as long as the immunology patents and depends on deals refilling the pipeline before the late-2030s exclusivity losses.

Trailing revenue rose about 5% to $64.4B and 2026 guidance points to high-single-digit growth, so Y1 growth moves from 8% to 9%. Target margin moves from 36% to 42% (about 17% relative, below the 20% threshold): adjusted operating margins run around 46%, Allergan amortization is fading, and I subtract roughly 4 points for recurring IPR&D and business-development spending, which is real reinvestment. Beta, sales-to-capital, horizon and terminal growth are unchanged; the last price-to-value gap of nearly 3x (well over 100%) forced a re-check, but only the margin evidence justifies a move.

Value drivers

Revenue growth (Y1)9.0%
Terminal growth2.5%
Forecast horizon10y
Target operating margin42.0%
Years to target margin4
Sales-to-capital1.40
Beta0.90
Failure probability1.0%
Cost of capital (WACC)8.6%
Terminal WACC9.0%

Valuation bridge

PV of explicit FCFF122.37B
PV of terminal value165.34B
Equity value223.14B
÷ shares → per share$126.28

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 70.18B 9.0% 24.0% 10.96B 4.14B 6.82B 6.28B
2 75.99B 8.3% 30.0% 14.83B 4.15B 10.68B 9.05B
3 81.73B 7.6% 36.0% 19.13B 4.10B 15.03B 11.72B
4 87.32B 6.8% 42.0% 23.84B 3.99B 19.85B 14.25B
5 92.65B 6.1% 42.0% 25.29B 3.81B 21.48B 14.19B
6 97.65B 5.4% 42.0% 26.66B 3.57B 23.09B 14.04B
7 102.20B 4.7% 42.0% 27.90B 3.25B 24.65B 13.80B
8 106.23B 3.9% 42.0% 29.00B 2.88B 26.12B 13.46B
9 109.66B 3.2% 42.0% 29.94B 2.45B 27.49B 13.04B
10 112.40B 2.5% 42.0% 30.68B 1.96B 28.73B 12.54B

Key risks

  • IRA Medicare price negotiation and most-favored-nation pricing pressure on Skyrizi, Rinvoq and Vraylar
  • Overpaying in business development (IPR&D write-offs) as AbbVie buys pipeline to cover late-2030s exclusivity losses
  • $62B of net debt and dividend commitments limit flexibility if growth slows
  • Competition from oral IL-23 and TL1A drugs in inflammatory bowel disease and psoriasis

Catalysts

  • Rinvoq label expansions (alopecia areata, lupus, vitiligo) and Skyrizi share gains in IBD
  • Emraclidine/tavapadon and oncology ADC readouts that show the post-2030 pipeline can carry growth

History

DatePriceIntrinsicMoSRating
2026-11-04$286.00 $126.28 -55.8% SELL
2026-10-01$261.59 $91.58 -65.0% SELL
2026-08-28$258.15 $33.24 -87.1% STRONG SELL
2026-07-28$256.91 $43.64 -83.0% STRONG SELL
2026-06-24$234.76 $51.07 -78.2% STRONG SELL
2026-06-21$216.49 $51.27 -76.3% SELL